Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain
Authors:
- Carsten K. NielsenCNCarsten K. Nielsen
- Fraser B. RossFRFraser B. Ross
- Shahrdad LotfipourSLShahrdad Lotfipour
- Kamal S. SainiKSKamal S. Saini
- Stephen R. EdwardsSEStephen R. Edwards
- Maree T. SmithMSMaree T. Smith
- 1 December 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 132 (3) , 289-300
Abstract
Previously, we reported that oxycodone is a putative kappa-opioid agonist based on studies where intracerebroventricular (i.c.v.) pre-treatment of rats with the kappa-selective opioid antagonist, nor-binaltorphimine (nor-BNI), abolished i.c.v. oxycodone but not morphine antinociception, whereas pretreatment with i.c.v. naloxonazine (mu-selective antagonist) produced the opposite effects. In the present study, we used behavioural experiments in rat models of mechanical and biochemical nerve injury together with radioligand binding to further examine the pharmacology of oxycodone. Following chronic constriction injury (CCI) of the sciatic nerve in rats, the antinociceptive effects of intrathecal (i.t.) oxycodone, but not i.t. morphine, were abolished by nor-BNI. Marked differences were found in the antinociceptive properties of oxycodone and morphine in streptozotocin (STZ)-diabetic rats. While the antinociceptive efficacy of morphine was abolished at 12 and 24 weeks post-STZ administration, the antinociceptive efficacy of s.c. oxycodone was maintained over 24 weeks, albeit with an approximately 3- to 4-fold decrease in potency. In rat brain membranes irreversibly depleted of mu- and delta-opioid binding sites, oxycodone displaced [(3)H]bremazocine (kappa(2)-selective in depleted membranes) binding with relatively high affinity whereas the selective mu- and delta-opioid ligands, CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2)) and DPDPE ([D-Pen(2,5)]-enkephalin), respectively, did not. In depleted brain membranes, the kappa(2b)-ligand, leu-enkephalin, prevented oxycodone's displacement of high-affinity [(3)H]bremazocine binding, suggesting the notion that oxycodone is a kappa(2b)-opioid ligand. Collectively, the present findings provide further support for the notion that oxycodone and morphine produce antinociception through distinctly different opioid receptor populations. Oxycodone appears to act as a kappa(2b)-opioid agonist with a relatively low affinity for mu-opioid receptors.Keywords
This publication has 54 references indexed in Scilit:
- Sexual dimorphism in the antinociception mediated by kappa opioid receptors in the rat temporomandibular jointNeuroscience Letters, 2004
- Comparison of epidural morphine and oxycodone for pain after abdominal surgeryJournal of Clinical Anesthesia, 1997
- The reduction of antinociceptive effect of morphine administered intraventricularly is correlated with the decrease of serotonin release from the spinal cord in streptozotocin-induced diabetic ratsGeneral Pharmacology: The Vascular System, 1996
- Streptozotocin-induced diabetes selectively enhances antinociception mediated by δ1-but not δ2-opioid receptorsLife Sciences, 1994
- The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to ratsLife Sciences, 1994
- Prazosin blocks the pressor but not the regional circulatory effects of diaspirin crosslinked hemoglobinLife Sciences, 1994
- Selective labeling of κ2 opioid receptors in rat brain by [125I]IOXY: Interaction of opioid peptides and other drugs with multiple κ2a binding sitesPeptides, 1993
- Mu receptor binding of some commonly used opioids and their metabolitesLife Sciences, 1991
- Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brainPeptides, 1990
- A high affinity, highly selective ligand for the delta opioid receptor: [3H]-[D-PEN2, pCl-PHE4, D-PEN5]enkephalinLife Sciences, 1989